Table 3 Results of the Base-Case Analysis
Treatment | Total cost $ | LYs | ICER $/LY a | QALYs | ICER $/QALY b |
|---|---|---|---|---|---|
Overall Patients | |||||
Bevacizumab | 329,087 | 6.46 | NA | 5.23 | NA |
Olaparib plus bevacizumab | 622,743 | 8.42 | 136,218 | 7.08 | 158,729 |
Patients with BRCA Mutations | |||||
Bevacizumab | 440,453 | 6.96 | NA | 5.58 | NA |
Olaparib plus bevacizumab | 706,121 | 10.89 | 66,120 | 8.92 | 79,434 |
Patients with HRD positive | |||||
Bevacizumab | 374,452 | 7.32 | NA | 5.91 | NA |
Olaparib plus bevacizumab | 617,198 | 9.36 | 117,747 | 7.62 | 141,636 |
Patients with HRD positive without BRCA Mutations | |||||
Bevacizumab | 332,850 | 6.38 | NA | 5.16 | NA |
Olaparib plus bevacizumab | 526,642 | 7.52 | 169,733 | 6.13 | 200,595 |